Physician
Fairbanks, John
Fairbanks, John was paid $414K by Medicaid between Jan 2018 and Dec 2021, across 22 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 30% of everything it billed.
33Billing provider infoFAIRBANKS, JOHN
VIDALIA, LA 71373
VIDALIA, LA 71373
33aNPI1669491288assigned 07/18/2006
33bProvider typeOrthopaedic Surgery Physician
28Total paid$414K
24GClaims8,576
24DCodes billed22
24AFirst – last monthJan 2018 – Dec 2021
Compared with peers
Next to other Orthopaedic Surgery Physician providers in Louisiana
Rank by total paid#8 of 46
Median peer was paid$10K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 939 | $35K | |
| 2019 | 1,298 | $43K | |
| 2020 | 3,111 | $162K | |
| 2021 | 3,228 | $174K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 30% | 2,156 | 2,054 | $124K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 2,106 | 1,966 | $81K |
| L0648 | Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 12% | 47 | 45 | $48K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 741 | 703 | $43K |
| 72110 | 7.3% | 962 | 932 | $30K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 6.6% | 476 | 462 | $27K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.2% | 194 | 192 | $17K |
| 72170 | 3.2% | 806 | 781 | $13K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 283 | 272 | $7K |
| 20611 | 1.3% | 87 | 84 | $5K | |
| 72040 | <1% | 188 | 181 | $4K | |
| 72052 | <1% | 93 | 92 | $4K |
10 more codes
| 62323 | <1% | 28 | $3K | |
| 73030 | <1% | 158 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 13 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 26 | $1K |
| 73502 | <1% | 35 | $740.22 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $521.80 |
| 73564 | <1% | 14 | $342.86 | |
| 73562 | <1% | 14 | $280.28 | |
| 73565 | <1% | 14 | $263.51 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 123 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.